Effects of dietary cholesterol on plasma lipoproteins in smith-lemli-opitz syndrome

feature-image

Play all audios:

Loading...

ABSTRACT Smith-Lemli-Opitz syndrome is a condition of impaired cholesterol synthesis that is caused by mutations in _DHCR7_ encoding 7-dehydrocholesterol-Δ7 reductase. Birth defects and


mental retardation are characteristic. Deficient plasma and tissue cholesterol and excess cholesterol precursors 7 and 8 dehydrocholesterol (7DHC and 8DHC) contribute to the pathogenesis.


Cholesterol is transported to tissues _via_ lipoproteins. We measured the effect of dietary cholesterol (egg yolk) on plasma lipoproteins to evaluate this potential treatment. We used the


enzymatic method to measure total sterols in lipoproteins (_n_ = 12) and plasma (_n_ = 16). In addition, we analyzed individual plasma sterols by a gas chromatographic method. Samples were


evaluated after 3 wk of a cholesterol-free diet and after 6–19 mo of dietary cholesterol. We also analyzed the distribution of sterols in lipoproteins and the apolipoprotein E genotype.


Dietary cholesterol significantly increased the total sterols in plasma (2.22 ± 0.13 to 3.10 ± 0.22; mean ± SEM; _p_ < 0.002), in LDL (0.98 ± 0.13 to 1.52 ± 0.17 mM), and in HDL (0.72 ±


0.04 to 0.92 ± 0.07). Plasma cholesterol increased (1.78 ± 0.16 to 2.67 ± 0.25 mM; _p_ < 0.007) and plasma 7DHC decreased in 10 children, but the mean decrease was not significant. The


distribution of individual sterols in each lipoprotein fraction was similar to the distribution in plasma. The baseline cholesterol and the response to dietary cholesterol was the same in


children with 3/3 and 3/4 apolipoprotein E genotypes. Dietary cholesterol increased total sterols in plasma, LDL, and HDL in children with Smith-Lemli-Opitz syndrome. These favorable


increases in the lipoproteins are potentially therapeutic for this condition. SIMILAR CONTENT BEING VIEWED BY OTHERS EFFECTS OF PHYTOSTEROL SUPPLEMENTATION ON LIPOPROTEIN SUBFRACTIONS AND


LDL PARTICLE QUALITY Article Open access 15 May 2024 METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS IN HEALTH AND DYSLIPIDAEMIA Article 22 March 2022 METABOLOMIC PROFILING OF A CHOLESTEROL


LOWERING PLANT-BASED DIET FROM TWO RANDOMIZED CONTROLLED FEEDING TRIALS Article 22 April 2025 MAIN The Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive condition with multiple


malformations and mental retardation (OMIM #270400). SLOS is caused by mutations in the gene encoding the final enzyme in the cholesterol biosynthetic pathway 7-dehydrocholesterol


Δ7-reductase (DHCR7; E.C 1.3.1.21). Although the syndrome was initially described in 1964 (1), it was not until 30 y later that deficiency of a cholesterol biosynthetic enzyme was identified


as the cause of the syndrome (2–4). The identification and cloning of the gene defective in SLOS, _DHCR7_, were reported in 1998 (5–7). Currently, >80 different mutations in _DHCR7_ have


been found to be associated with SLOS (8,9). SLOS is characterized clinically by microcephaly, cleft palate, dysmorphic facies, limb abnormalities (especially syndactyly of toes 2 and 3),


genital anomalies, endocrine malfunction, cataracts, malformation in the heart and kidney, mental retardation, feeding difficulties, and growth retardation (10). Clinical features are


variable in severity, presumably reflecting the specific causative mutations and the extent of the decrease in enzyme activity. Some mildly affected patients exhibit only a few of the


described features. The biochemical consequences of the enzyme deficiency include abnormally low or low-normal cholesterol concentrations along with accumulation of the precursor that is the


substrate of DHCR7, 7-dehydrocholesterol (7DHC), and its derivative 8-dehydrocholesterol (8DHC). Treatment is sought to correct the biochemical imbalance and improve physical and


psychomotor development. Several studies have been conducted to evaluate the effects of supplemental and dietary cholesterol as a potential treatment for this condition (11–19). These


studies evaluated the effect of supplemental and/or dietary cholesterol on plasma sterol (cholesterol, 7DHC, 8DHC) concentrations. In the current study, in addition to measuring plasma


sterols, we analyzed lipoproteins (LDL, HDL, VLDL, and triglyceride) to test the hypothesis that dietary cholesterol will increase total sterols in LDL. A second objective was to determine


the distribution of cholesterol, 7DHC, and 8DHC in lipoproteins because this has not been reported previously. We measured lipoprotein sterols at baseline (after 3 wk of an essentially


cholesterol-free diet) and after 6–19 mo of dietary cholesterol primarily from egg yolk. A third objective was to determine whether apolipoprotein E (apoE) genotype affects the response to


dietary cholesterol. METHODS SUBJECTS AND STUDY DESIGN. Sixteen children with SLOS were enrolled; two of the children were siblings. We have previously reported data on plasma sterol levels,


sterol synthesis, urinary mevalonate, and DNA mutations in as many as 14 of these children (19–22), but we have not previously reported lipoprotein data. All study children had clinical


features of SLOS and elevated 7DHC and 8DHC plasma concentrations diagnostic of SLOS. The children (Table 1) were admitted to the Oregon Health & Science University General Clinical


Research Center for 1-wk periods. Parents were instructed to feed their child an essentially cholesterol-free diet (baseline diet) at home for 3–4 wk before the first admission to establish


baseline conditions. The cholesterol content of these diets ranged from 0.4 to 3.3 mg cholesterol · kg−1 · d−1; one child was breast fed and consumed 14 mg cholesterol · kg−1 · d−1 contained


in breast milk. The baseline diet period was repeated when the initial study was unsuccessful as a result of illness, nonadherence to diet, difficulties with sample collection, or other


reason. During these admissions, the baseline diet was continued under metabolic ward conditions. On discharge, children were prescribed dietary cholesterol as egg yolk and/or butter fat. In


a few cases, crystalline cholesterol in oil or emulsion was prescribed. For all other admissions, the children continued to receive cholesterol. Children returned every 3–12 mo for


monitoring. Blood samples were evaluated during the last week of the baseline diet and after 6–19 mo of dietary cholesterol. Details of the diets are described in previous reports (18,19).


In summary, children aged 0–6 mo were fed one half egg yolk/d; children aged 6–12 mo were fed 1 egg yolk/d; and children aged 12 mo or older were fed 1.5 to 2 egg yolks/d. On the basis of an


estimate of 210 mg of cholesterol per egg yolk, the children received ∼18–60 mg · kg−1 · d−1 of cholesterol. Eggs were hardboiled, and the yolks removed and mixed with formula, breast milk,


or solid food, according to the child's regular diet. At times, egg yolk was cooked in formula or milk. Egg yolks were also provided as powdered egg yolk (subjects 5 and 9) or as whole


eggs (in subject 8 for 46% of the duration of the dietary cholesterol period). Powdered egg yolk was stored at 4°C to prevent oxidation of its cholesterol. Six children received butter fat,


heavy cream, crystalline cholesterol in soybean oil (16), or crystalline cholesterol in an aqueous suspension (23) instead of egg yolk during some or all of the supplemental cholesterol


period. Table 2 describes the source and duration of the supplemental cholesterol (other than egg yolk) for these children. Feeding difficulties are common in SLOS, and seven of the 16


children in our study required tube feeding. The same dietary protocols were used for children who were tube fed or orally fed. These studies were approved by the Oregon Health & Science


University (Portland, OR) Institutional Review Board; the parents gave informed consent for the participation of their child. LIPOPROTEIN AND PLASMA STEROL ANALYSIS. Total sterols in each


lipoprotein fraction and in plasma as well as plasma triglycerides were measured by the standard clinical method (enzymatic method) with a Hitachi 704 Chemistry Analyzer, in compliance with


the standardization and surveillance programs of the Centers for Disease Control and Prevention Laboratory (Atlanta, GA) (24,25). This enzymatic method uses cholesterol esterase and


cholesterol oxidase and overestimates plasma cholesterol concentrations from children with SLOS because dehydrocholesterols are substrates for cholesterol oxidase and contribute to the


resulting value (26). In plasma, the sum of the sterols (measured individually by gas chromatographic method) was similar to the total sterols (measured by enzymatic method) at baseline and


after dietary cholesterol (_R_2 = 0.98). Therefore, we assumed for subsequent analyses by the enzymatic method that each value represented “total sterols,” that is, cholesterol, 7DHC, and


8DHC. We measured the concentrations of individual sterols (cholesterol, 7DHC, and 8DHC) in each lipoprotein fraction (LDL, HDL, and VLDL) after separation by ultracentrifugation (24) (_n_ =


2). This ultracentrifugation step requires more blood than is routinely obtained in these small children, so we were able to do this only with two children. Both children were receiving


dietary cholesterol at the time of measurement. In all of the children, we measured the concentrations of individual sterols in plasma. These individual plasma sterol concentrations were


measured by capillary-column gas chromatography with a CP-Wax 57 column (25 M, 0.32 mm ID; Chrompack Co., Raritan, NJ) (5,20). Internal standard (5α-cholestane) and an authentic standard of


the cholesterol were used for calibration. In the two children, the distribution of individual sterols in each lipoprotein was the same as the distribution in plasma. Assuming that this was


the case for all of the children, we calculated the concentrations of cholesterol, 7DHC, and 8DHC in each lipoprotein fraction. For example, the concentration of cholesterol in LDL equals


the ratio of cholesterol to total sterols in plasma sample (gas chromatographic method) multiplied by the total sterol concentration in LDL (enzymatic method). Data are expressed as means ±


SEM. Statistical analysis of differences between means was determined using a two-tailed _t_ test for paired samples. APOE GENOTYPING. The apoE gene has three alleles, ε2, ε3, and ε4, coding


for the three major isoforms (E2, E3, and E4) of this protein. The alleles were identified by PCR amplification of nucleotides 2823–3093 followed by restriction endonuclease digestion with


_Hha_I. The six possible genotypes were determined from the sizes of the DNA fragments (27). RESULTS EFFECT OF DIETARY CHOLESTEROL ON LIPOPROTEINS AND TOTAL STEROLS. By the enzymatic method,


we measured total sterols in plasma (16 children) and total sterols in each lipoprotein fraction (12 children). Measurements that were taken at baseline (after 3 wk of an essentially


cholesterol-free diet) were compared with measurements after 6–19 mo of dietary cholesterol. The total sterols in plasma increased from 2.22 to 3.10 mM (_p_ < 0.002; Table 3). Six


children received alternative sources of cholesterol instead of egg yolk during some or all of the supplemental cholesterol period. The total sterols in this subgroup increased from 2.38 ±


0.28 to 3.26 ± 0.28 mM. Total sterols in LDL (enzymatic method) increased significantly (from 0.98 to 1.52 mM; _p_ < 0.02) in parallel with the increase in total plasma sterols. HDL


increased similarly from 0.72 to 0.92 mM (_p_ < 0.03). There were no changes in total sterols in VLDL (0.49 to 0.58 mM; _p_ = 0.48) or in plasma triglyceride concentrations (1.11 to 1.24


mM; _p_ = 0.49) in response to the dietary cholesterol. Under normal conditions, changes in dietary cholesterol do not affect VLDL cholesterol or plasma triglyceride concentrations (28). In


children 5–9 y of age, the normal triglyceride concentration in fasting plasma ranges from 31 to 104 mg/dL (29). Our values for triglycerides are slightly higher, likely because fasting


samples could not be obtained from infants. EFFECT OF DIETARY CHOLESTEROL ON PLASMA CONCENTRATIONS OF CHOLESTEROL, 7DHC, AND 8DHC. To determine whether the increase in total sterols resulted


specifically from an increase in the cholesterol component of plasma, we measured plasma cholesterol, 7DHC, and 8DHC concentrations in 16 SLOS children at baseline (after 3 wk of


essentially cholesterol-free diet) and after 6–19 mo of dietary cholesterol. Dietary cholesterol raised plasma cholesterol from 1.78 to 2.67 mM (_p_ < 0.007; Table 4). Not only did the


concentration of plasma cholesterol increase, but also the ratio of cholesterol relative to the sum of all sterols increased from 0.79 to 0.84. Dietary cholesterol did not significantly


decrease the mean plasma 7DHC (Table 4) or 8DHC (0.23–0.21 mM and 0.19–0.20 mM, respectively). At baseline, there was no correlation between the concentrations of cholesterol and 7DHC. After


dietary cholesterol, however, there was a significant negative correlation (_R_2 = 0.62, _p_ < 0.01; Fig. 1). Children who responded to the dietary cholesterol with the greatest increase


in plasma cholesterol concentrations tended to obtain the lowest 7DHC concentrations. DISTRIBUTION OF STEROLS WITHIN EACH LIPOPROTEIN FRACTION. The increase in total sterols in LDL and HDL


could result from an increase either in cholesterol or in the precursor sterols 7DHC or 8DHC. The plasma samples from two children had an adequate volume to separate the VLDL, LDL, and HDL


by ultracentrifugation. We then measured the individual sterol concentrations (cholesterol, 7DHC, and 8DHC) by gas chromatographic method in each fraction. We compared the distribution of


individual sterols in each lipoprotein with the distribution of individual sterols measured in plasma (Fig. 2). The concentrations of total sterols in each of these two children (subjects 7


and 9) were different from one another (2.43 and 1.24 mM, respectively). In addition, the distribution of cholesterol relative to the total sterols in plasma was different in these two


children (90 and 70%, respectively). For each child individually, however, the distribution of cholesterol, 7DHC, and 8DHC (relative to total sterols) in each lipoprotein fraction was the


same as the distribution in plasma (Fig. 2). Assuming that this is true for all cases, we calculated the concentration of cholesterol in LDL and HDL for each child (_n_ = 12). Results showed


that LDL cholesterol increased from 0.73 ± 0 0.13 to 1.31 ± 0.18 mM (_p_ < 0.02) and HDL cholesterol increased from 0.57 ± 0.05 to 0.79 ± 0.08 mM (_p_ < 0.03). The concentrations of


7DHC in LDL (0.10 mM and 0.11 mM) or 8DHC in LDL (0.09 and 0.10 mM) did not change. LACK OF EFFECT OF APOE GENOTYPE ON PLASMA CHOLESTEROL AND ON EFFICACY OF DIETARY CHOLESTEROL. Plasma


sterols in SLOS children varied widely at baseline and after dietary cholesterol. Of the three isoforms of apoE, the E4 isoform is associated with increased concentration of plasma


cholesterol (30). We determined whether apoE genotype could account for some of this variability. Three of the SLOS children had the 3/4 apoE genotype, whereas nine had the 3/3 genotype.


Plasma cholesterol concentrations, however, were similar in SLOS children with either genotype at baseline (1.74 _versus_ 1.80 mM; _p_ = 0.90) and after 6–19 mo of dietary cholesterol (2.62


_versus_ 2.81 mM; _p_ = 0.80; 3/4 and 3/3, respectively). DISCUSSION Cholesterol deficiency is characteristic of SLOS and may be a major contributor to the characteristic clinical features.


Cholesterol is an essential component of cell membranes and nervous system neurons and myelin, as well as serving as the substrate for important biologic compounds, including bile acids and


steroid hormones. Recently, cholesterol was shown to be an essential component of the lipid rafts involved in intracellular trafficking of proteins and lipids (31) and cell surface signaling


proteins (32). In addition, cholesterol has been shown to promote CNS synaptogenesis (33). Cholesterol also plays a critical role during fetal development. The cholesterol molecule is a


covalently bound component of active hedgehog proteins, a family of embryonic signaling proteins (34). Cholesterol deficiency could alter the function of the hedgehog signaling pathway. In


SLOS, some of the pathologic characteristics may also be due to accumulation of cholesterol precursors. For example, accumulation of 7DHC in the brain has been associated with impaired


learning in rats (35). 7DHC has also been shown to be teratogenic in rat embryos (36). Therefore, treatment for SLOS that normalizes plasma and tissue cholesterol levels while decreasing


accumulation of potentially toxic cholesterol intermediates and metabolites is sought. Dietary cholesterol has been considered a potential treatment. Lipoproteins are essential for transport


of dietary cholesterol from the intestines to the other tissues of the body as well as for cellular uptake of cholesterol. We measured total sterols in each lipoprotein fraction in 12


children. The total sterols significantly increased in LDL and HDL in response to dietary cholesterol. The ratios of noncholesterol sterols to cholesterol in serum do not always predict the


ratios in the different lipoproteins (37). Therefore, in two children, the concentration of each sterol within each lipoprotein was measured to determine the distribution of the sterols in


lipoproteins. In these two children, the distribution of individual sterols within each lipoprotein fraction was shown to be the same as the distribution in plasma. We calculated the


concentration of each sterol in each lipoprotein fraction in 12 children using the assumption that plasma sterol distribution equaled lipoprotein sterol distribution. These results showed


that after dietary cholesterol, _1_) the cholesterol concentrations in LDL and HDL increased, and _2_) there was not a preferential increase of 7DHC or 8DHC in either LDL or HDL. The


increases in LDL and HDL cholesterol in these children in response to dietary cholesterol could provide a larger pool of cholesterol available for tissue uptake. It has been shown that


125I-HDL2 from plasma of patients with abetalipoproteinemia was bound, taken up, and degraded by cultured human fibroblasts (37a). This suggests that HDL in addition to LDL can transport


cholesterol to tissues. Kinetic studies will be needed to determine whether there is a corresponding increase in LDL and HDL cholesterol uptake by cholesterol-deficient tissues in SLOS. Only


two published studies have reported lipoprotein data in SLOS patients. Pierquin _et al._ (38) described one severely affected child. This child had low concentrations of total sterols in


LDL (13 mg/dL) and HDL (8 mg/dL) and a low concentration of apoA-I (67 mg/dL), the major protein of HDL, as compared with normal ranges. Behulova _et al._ (39) performed similar measurements


in eight children who had SLOS and were not receiving supplemental or dietary cholesterol. Five of the children were severely affected, and three had less severe clinical features. All


eight children studied had low concentrations of total sterols in LDL (range: 0–1.18 mM) and HDL (0.13–0.84 mM) and low concentrations of apoA-I (<0.12–0.94 g/dL). The concentrations of


total sterols in VLDL were normal or above normal, and the concentrations of apoB were normal or borderline low. Neither the effect of dietary cholesterol on lipoproteins nor the


distribution of the individual sterols (in lipoprotein fractions or in plasma) was measured in these two studies. The effect of dietary cholesterol on plasma sterols was similar to our


previous report (19). After 6–19 mo of dietary cholesterol with egg yolk (in most cases), the mean plasma cholesterol in children with SLOS significantly increased when compared with the


mean concentration at baseline. The increase in cholesterol (57%, _n_ = 16) found in the current study was similar to the increase in cholesterol (55%, _n_ = 7) after 1–3 mo of dietary


cholesterol in our earlier study (19). These percentage increases were greater than those increases seen in adults who were given high-cholesterol diets (40). After dietary cholesterol,


plasma cholesterol rose to above the fifth percentile in four children of the current study, 3.18 mM for normal children aged 5–9 y (29). Although 10 children showed a decrease in plasma


7DHC (range: 8–77%), six children had an increase or no change. After dietary cholesterol, the lowest concentration of 7DHC in the SLOS children, 0.04 mM, was still higher than normal,


0.00026 mM (41). The bioavailability of egg yolk cholesterol _versus_ crystalline cholesterol has not been reported recently. We chose to use egg yolk as the source of cholesterol in most


subjects because there is some evidence that it is more effective in raising plasma cholesterol concentrations. In normal adults, dietary egg yolk increased plasma cholesterol concentrations


more readily than crystalline cholesterol supplementation (69 _versus_ 19 mg/dL), even though the subjects consumed lower amounts of cholesterol in the form of dietary egg yolks (475–1425


mg/d) than the amounts consumed as cholesterol in the crystalline form (1200–3600 mg/d) (42). In this present study, the increases in plasma concentrations were similar in both groups.


However, the number of children is too small to determine whether the source of cholesterol made a difference in the plasma sterol response. The absorption of cholesterol from the intestine


is complex (43) and may be dependent on many factors, including emulsification, micelle formation (44), and cholesterol transporters (45,46). Dietary cholesterol presumably would lower


plasma 7DHC and 8DHC in SLOS by inhibiting hepatic hydroxymethyl glutaryl (HMG) CoA reductase through feedback inhibition of this rate-limiting enzyme. We have shown that dietary cholesterol


(for 2 mo or 2 y) decreased HMG CoA reductase activity as measured by the amount of mevalonate in 24-h urine samples. Only after 2 y, however, was there a decrease in plasma 7DHC (_n_ = 4)


(19). These results and the wide range of responses of plasma 7DHC in our current study reflect the complex regulation of the cholesterol biosynthetic pathway. CONCLUSION This is the first


report of the effect of dietary cholesterol on sterols in lipoproteins in children with SLOS and of the distribution of cholesterol, 7DHC, and 8DHC in lipoproteins. Increase of total sterols


in plasma in response to dietary cholesterol was paralleled by increases of total sterols in LDL and HDL. Calculated concentrations of cholesterol in LDL and HDL also increased. This bodes


well for potential therapy of SLOS, because the increased LDL and HDL cholesterol provides a larger pool of cholesterol for tissue uptake. The plasma 7DHC concentrations did not return to


normal in the current study. Although dietary cholesterol inhibits HMG CoA reductase in SLOS (19), further inhibition, perhaps by statin drugs, may be necessary to normalize the 7DHC.


ABBREVIATIONS * apoE: apolipoprotein E * DHCR7: 7-dehydrocholesterol Δ7-reductase * HMG: hepatic hydroxymethyl glutaryl * SLOS: Smith-Lemli-Opitz syndrome * 7DHC: 7-dehydrocholesterol *


8DHC: 8-dehydrocholesterol REFERENCES * Smith DW, Lemli L, Opitz JM 1964 A newly recognized syndrome of multiple congenital anomalies. _J Pediatr_ 64: 210–217 Article  CAS  Google Scholar  *


Irons M, Elias ER, Salen G, Tint GS, Batta AK 1993 Defective cholesterol biosynthesis in Smith-Lemli-Opitz syndrome. _Lancet_ 341: 1414 Article  CAS  Google Scholar  * Tint GS, Irons M,


Elias ER, Batta AK, Frieden R, Chen TS, Salen G 1994 Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome. _N Engl J Med_ 330: 107–113 Article  CAS  Google


Scholar  * Shefer S, Salen G, Batta AK, Honda A, Tint GS, Irons M, Elias ER, Chen TC, Holick MF 1995 Markedly inhibited 7-dehydrocholesterol-delta 7-reductase activity in liver microsomes


from Smith-Lemli-Opitz homozygotes. _J Clin Invest_ 96: 1779–1785 Article  CAS  Google Scholar  * Wassif CA, Maslen C, Kachilele-Linjewile S, Lin D, Linck LM, Connor WE, Steiner RD, Porter


FD 1998 Mutations in the human sterol delta7-reductase gene at 11q12–13 cause Smith-Lemli-Opitz syndrome. _Am J Hum Genet_ 63: 55–62 Article  CAS  Google Scholar  * Waterham HR, Wijburg FA,


Hennekam RC, Vreken P, Poll-The BT, Dorland L, Duran M, Jira PE, Smeitink JA, Wevers RA, Wanders RJ 1998 Smith-Lemli-Opitz syndrome is caused by mutations in the 7-dehydrocholesterol


reductase gene. _Am J Hum Genet_ 63: 329–338 Article  CAS  Google Scholar  * Fitzky BU, Witsch-Baumgartner M, Erdel M, Lee JN, Paik YK, Glossmann H, Utermann G, Moebius FF 1998 Mutations in


the Delta7-sterol reductase gene in patients with the Smith-Lemli-Opitz syndrome. _Proc Natl Acad Sci USA_ 95: 8181–8186 Article  CAS  Google Scholar  * Waterham HR, Wanders RJ 2000


Biochemical and genetic aspects of 7-dehydrocholesterol reductase and Smith-Lemli-Opitz syndrome. _Biochim Biophys Acta_ 1529: 340–356 Article  CAS  Google Scholar  * Nowaczyk MJ, Nakamura


LM, Waye JS 2001 DHCR7 and Smith-Lemli-Opitz syndrome. _Clin Invest Med_ 24: 311–317 CAS  PubMed  Google Scholar  * Battaile KP, Steiner RD 2000 Smith-Lemli-Opitz syndrome: the first


malformation syndrome associated with defective cholesterol synthesis. _Mol Genet Metab_ 71: 154–162 Article  CAS  Google Scholar  * Irons M, Elias ER, Tint GS, Salen G, Frieden R, Buie TM,


Ampola M 1994 Abnormal cholesterol metabolism in the Smith-Lemli-Opitz syndrome: report of clinical and biochemical findings in four patients and treatment in one patient. _Am J Med Genet_


50: 347–352 Article  CAS  Google Scholar  * Nwokoro NA, Hyde B, Mulvihill JJ 1994 Smith-Lemli-Opitz syndrome: biochemical before clinical diagnosis; early dietary management. _Am J Med


Genet_ 50: 375–376 Article  CAS  Google Scholar  * Ullrich K, Koch HG, Meschede D, Flotmann U, Seedorf U 1996 Smith-Lemli-Opitz syndrome: treatment with cholesterol and bile acids.


_Neuropediatrics_ 27: 111–112 Article  CAS  Google Scholar  * van Rooij A, Nijenhuis AA, Wijburg FA, Schutgens RB 1997 Highly increased CSF concentrations of cholesterol precursors in


Smith-Lemli-Opitz syndrome. _J Inherit Metab Dis_ 20: 578–580 Article  CAS  Google Scholar  * Nwokoro NA, Mulvihill JJ 1997 Cholesterol and bile acid replacement therapy in children and


adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. _Am J Med Genet_ 68: 315–321 Article  CAS  Google Scholar  * Irons M, Elias ER, Abuelo D, Bull MJ, Greene CL, Johnson VP, Keppen L, Schanen


C, Tint GS, Salen G 1997 Treatment of Smith-Lemli-Opitz syndrome: results of a multicenter trial. _Am J Med Genet_ 68: 311–314 Article  CAS  Google Scholar  * Elias ER, Irons MB, Hurley AD,


Tint GS, Salen G 1997 Clinical effects of cholesterol supplementation in six patients with the Smith-Lemli-Opitz syndrome (SLOS). _Am J Med Genet_ 68: 305–310 Article  CAS  Google Scholar  *


Linck LM, Lin DS, Flavell D, Connor WE, Steiner RD 2000 Cholesterol supplementation with egg yolk increases plasma cholesterol and decreases plasma 7-dehydrocholesterol in Smith-Lemli-Opitz


syndrome. _Am J Med Genet_ 93: 360–365 Article  CAS  Google Scholar  * Pappu AS, Steiner RD, Connor SL, Flavell DP, Lin DS, Hatcher L, Illingworth DR, Connor WE 2002 Feedback inhibition of


the cholesterol biosynthetic pathway in patients with Smith-Lemli-Opitz syndrome as demonstrated by urinary mevalonate excretion. _J Lipid Res_ 43: 1661–1669 Article  CAS  Google Scholar  *


Steiner RD, Linck LM, Flavell DP, Lin DS, Connor WE 2000 Sterol balance in the Smith-Lemli-Opitz syndrome. Reduction in whole body cholesterol synthesis and normal bile acid production. _J


Lipid Res_ 41: 1437–1447 CAS  PubMed  Google Scholar  * Linck LM, Hayflick SJ, Lin DS, Battaile KP, Ginat S, Burlingame T, Gibson KM, Honda M, Honda A, Salen G, Tint GS, Connor WE, Steiner


RD 2000 Fetal demise with Smith-Lemli-Opitz syndrome confirmed by tissue sterol analysis and the absence of measurable 7-dehydrocholesterol Delta(7)-reductase activity in chorionic villi.


_Prenat Diagn_ 20: 238–240 Article  CAS  Google Scholar  * Krakowiak PA, Nwokoro NA, Wassif CA, Battaile KP, Nowaczyk MJ, Connor WE, Maslen C, Steiner RD, Porter FD 2000 Mutation analysis


and description of sixteen RSH/Smith-Lemli-Opitz syndrome patients: polymerase chain reaction-based assays to simplify genotyping. _Am J Med Genet_ 94: 214–227 Article  CAS  Google Scholar 


* Martin A, Koenig K, Scahill L, Tierney E, Porter FD, Nwokoro NA 2001 Smith-Lemli-Opitz syndrome. _J Am Acad Child Adolesc Psychiatry_ 40: 506–507 Article  CAS  Google Scholar  * Lipid


Research Clinics Program, 1982 Manual of Laboratory Operations, Lipid and Lipoprotein Analysis, 2nd Ed. _Department of Health and Human Services (NIH)_, Bethesda * Wiebe DA, Bernert JT Jr


1984 Influence of incomplete cholesteryl ester hydrolysis on enzymic measurements of cholesterol. _Clin Chem_ 30: 352–356 CAS  PubMed  Google Scholar  * Jira PE, de Jong JG, Janssen-Zijlstra


FS, Wendel U, Wevers RA 1997 Pitfalls in measuring plasma cholesterol in the Smith-Lemli-Opitz syndrome. _Clin Chem_ 43: 129–133 CAS  PubMed  Google Scholar  * Tsukamoto K, Watanabe T,


Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T 1993 Determination by PCR-RFLP of apo E genotype in a Japanese population. _J Lab Clin Med_ 121: 598–602 CAS  PubMed 


Google Scholar  * Raymond TL, Connor WE, Lin DS, Warner S, Fry MM, Connor SL 1977 The interaction of dietary fibers and cholesterol upon the plasma lipids and lipoproteins, sterol balance,


and bowel function in human subjects. _J Clin Invest_ 60: 1429–1437 Article  CAS  Google Scholar  * Kwiterovich PO Jr 1991 Plasma lipid and lipoprotein levels in childhood. _Ann NY Acad Sci_


623: 90–107 Article  CAS  Google Scholar  * Utermann G, Kindermann I, Kaffarnik H, Steinmetz A 1984 Apolipoprotein E phenotypes and hyperlipidemia. _Hum Genet_ 65: 232–236 Article  CAS 


Google Scholar  * Ikonen E 2001 Roles of lipid rafts in membrane transport. _Curr Opin Cell Biol_ 13: 470–477 Article  CAS  Google Scholar  * Kabouridis PS, Janzen J, Magee AL, Ley SC 2000


Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. _Eur J Immunol_ 30: 954–963 Article  CAS  Google Scholar  * Mauch DH,


Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW 2001 CNS synaptogenesis promoted by glia-derived cholesterol. _Science_ 294: 1354–1357 Article  CAS  Google Scholar  * Kelley


RI, Hennekam RC 2000 The Smith-Lemli-Opitz syndrome. _J Med Genet_ 37: 321–335 Article  CAS  Google Scholar  * Xu G, Servatius RJ, Shefer S, Tint GS, O'Brien WT, Batta AK, Salen G 1998


Relationship between abnormal cholesterol synthesis and retarded learning in rats. _Metabolism_ 47: 878–882 Article  CAS  Google Scholar  * Roux C, Wolf C, Mulliez N, Gaoua W, Cormier V,


Chevy F, Citadelle D 2000 Role of cholesterol in embryonic development. _Am J Clin Nutr_ 71: 1270S–1279S Article  CAS  Google Scholar  * Ketomaki A, Gylling H, Siimes MA, Vuorio A, Miettinen


TA 2003 Squalene and noncholesterol sterols in serum and lipoproteins of children with and without familial hypercholesterolemia. _Pediatr Res_ 53: 648–653 Article  Google Scholar  *


Illingworth DR, Alam NA, Sundberg EE, Hagemenas FC, Layman DL 1983 Regulation of low density lipoprotein receptors by plasma lipoproteins from patients with abetalipoproteineinemia. _Proc


Natl Acad Sci USA_ 80: 3475–3479 Article  CAS  Google Scholar  * Pierquin G, Peeters P, Roels F, Vamos E, Brucher JM, Tint GS, Honda A, Van Regemorter N 1995 Severe Smith-Lemli-Opitz


syndrome with prolonged survival and lipid abnormalities. _Am J Med Genet_ 56: 276–280 Article  CAS  Google Scholar  * Behulova D, Bzduch V, Skodova J, Dello Russo A, Corso G, Ponec J,


Kasanicka A 2000 Serum lipids and apolipoproteins in children with the Smith-Lemli-Opitz syndrome. _J Inherit Metab Dis_ 23: 413–415 Article  CAS  Google Scholar  * Connor WE, Connor SL 2002


Dietary cholesterol and coronary heart disease. _Curr Atheroscler Rep_ 4: 425–432 Article  Google Scholar  * Cunniff C, Kratz LE, Moser A, Natowicz MR, Kelley RI 1997 Clinical and


biochemical spectrum of patients with RSH/Smith-Lemli-Opitz syndrome and abnormal cholesterol metabolism. _Am J Med Genet_ 68: 263–269 Article  CAS  Google Scholar  * Connor WE, Hodges RE,


Bleiler RE 1961 The serum lipids in men receiving high cholesterol and cholesterol-free diets. _J Clin Invest_ 40: 894–901 Article  CAS  Google Scholar  * Ros E 2000 Intestinal absorption of


triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. _Atherosclerosis_ 151: 357–379 Article  CAS  Google Scholar  * Yao L, Heubi JE, Buckley


DD, Fierra H, Setchell KD, Granholm NA, Tso P, Hui DY, Woollett LA 2002 Separation of micelles and vesicles within lumenal aspirates from healthy humans: solubilization of cholesterol after


a meal. _J Lipid Res_ 43: 654–660 CAS  PubMed  Google Scholar  * Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N,


Graziano MP 2004 Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. _Science_ 303: 1201–1204 Article  CAS  Google Scholar  * Plat J, Mensink RP 2002 Increased


intestinal ABCA1 expression contributes to the decrease in cholesterol absorption after plant stanol consumption. _FASEB J_ 16: 1248–1253 Article  CAS  Google Scholar  Download references


ACKNOWLEDGEMENTS We thank Gary Sexton, Ph.D., for assistance with statistical analysis and Pam Smith and Carol Marsh for lipoprotein separation. We thank the children and families for


participation in the study and the staff of the Oregon Health & Science University General Clinical Research Center. We thank Sandra Banta-Wright, R.N., M.S.N., N.N.P., Daniel Marks,


M.D., and numerous other health care providers who assisted in the care of these children. We thank the many health care providers who kindly referred these children to us. AUTHOR


INFORMATION AUTHORS AND AFFILIATIONS * Department of Pediatrics, Department of Medicine, OR Health & Science University, Portland, 97239, OR Louise S Merkens & Robert D Steiner *


Division of Endocrinology, Department of Medicine, Metabolism and Nutrition, OR Health & Science University, Portland, 97239, OR William E Connor, Don S Lin & Donna P Flavell *


Department of Genetics, Kaiser Permanente Northwest, Portland, 97227, OR Leesa M Linck * Department of Molecular and Medical Genetics, Child Development and Rehabilitation Center,


Doernbecher Children's Hospital, OR Health & Science University, Portland, 97239, OR Leesa M Linck & Robert D Steiner Authors * Louise S Merkens View author publications You can


also search for this author inPubMed Google Scholar * William E Connor View author publications You can also search for this author inPubMed Google Scholar * Leesa M Linck View author


publications You can also search for this author inPubMed Google Scholar * Don S Lin View author publications You can also search for this author inPubMed Google Scholar * Donna P Flavell


View author publications You can also search for this author inPubMed Google Scholar * Robert D Steiner View author publications You can also search for this author inPubMed Google Scholar


CORRESPONDING AUTHOR Correspondence to Robert D Steiner. ADDITIONAL INFORMATION Supported by grants from the National Heart, Lung, and Blood Institute (PHS HL-64618 and HL-073980); National


Center for Research Resources (PHS 5 M01 RR000334 and PHS 3 M01 RR003344-33S3); National Institute for Child Health and Human Development, OR Child Health Research Center (PHS 5P30


HD33703-04); the American Academy of Pediatrics Section on Genetics and Birth Defects; the Collins Foundation; and the Smith-Lemli-Opitz Advocacy and Exchange. R.D.S. is a Clinical Associate


Physician Investigator of the Oregon Health & Science University General Clinical Research Center. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE


Merkens, L., Connor, W., Linck, L. _et al._ Effects of Dietary Cholesterol on Plasma Lipoproteins in Smith-Lemli-Opitz Syndrome. _Pediatr Res_ 56, 726–732 (2004).


https://doi.org/10.1203/01.PDR.0000141522.14177.4F Download citation * Received: 20 January 2004 * Accepted: 07 July 2004 * Issue Date: 01 November 2004 * DOI:


https://doi.org/10.1203/01.PDR.0000141522.14177.4F SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link


is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative